Recently luteinising hormone releasing hormone (LHRH) agonists have been shown to have direct inhibitory effects on human breast cancer cell lines in vitro and low affinity binding sites were demonstrated (Miller et al., 1985; Blankenstein et al., 1985) . LHRH binding sites have also been demonstrated in primary breast tumours (Eidne et al., 1985) . Therefore, LHRH agonists such as Zoladex (Goserelin) have been assessed for potential efficacy in postmenopausal breast cancer, on the assumption that a therapeutic effect may indicate a direct antitumour effect (Plowman et al., 1986; Waxman et al., 1985) , whereas in premenopausal women the major effect would be via ovarian suppression (Nicholson et al., 1985) . However, other endocrine effects may occur in post-menopausal women.
In the post-menopausal woman, adrenal and ovarian androgens are the main source of oestrogens (Judd et al., 1982 (Judd et al., , 1974 Grodin et al., 1973) . They are converted peripherally by aromatase to oestrone and oestradiol. Inhibitors of aromatase (e.g. aminoglutethimide) are effective endocrine therapies in the treatment of post-menopausal breast cancer (Harris et al., 1983c) and occasionally premenopausal breast cancer (Bezwoda et al., 1987; Wander et al., 1986) . In the latter case, it has been suggested that intratumour conversion of androgens to oestrogens may be important and direct inhibition may be important, without any detectable lowering of peripheral oestrogens (Miller et al., 1982; Bezwoda et al., 1987) .
Hydrocortisone alone can suppress adrenal androgen production (Harris et al., 1984) and hence lower peripheral oestrogen levels (Harris et al., 1984) . We have recently shown that the androgens produced by the post-menopausal ovary are under pituitary FSH and LH control (Dowsett et al., 1988 Table I .
Patients received monthly subcutaneous Zoladex, 3.6mg, after infiltration of the local site with lignocaine. Response was assessed by UICC criteria (Hayward et al., 1977) . After Zoladex failure, patients who had received no previous endocrine therapy were treated with Tamoxifen 20mg daily when appropriate.
Oestrone and oestradiol were measured by radio-immunoassays which we have previously described (Harris et al., 1983a; Dowsett et al., 1987 Other series report endocrine data as showing no significant changes in oestradiol or oestrone. However, details of the sensitivity of the assays were not presented in one study (Plowman et al., 1986) and in the other the lower limit of detection of oestradiol was 50 pmoll-1 (Waxman et (Clayton et al., 1985) . Another LHRH agonist, Buserelin, inhibits the growth of the human breast cancer cell line MCF7 at concentrations of 1 nM or greater (Miller et al., 1985; Foekens et al., 1986 (Dowsett et al., 1988) . Since these steroids are precursors of oestrogens, the latter were also decreased. The suppression of oestradiol is more marked than that of oestrone and this may be due to the greater suppression of testosterone rather than androstenedione (Dowsett et al., 1988) , which are the respective precursors of the oestrogens.
Because of the peripheral endocrine effects, it is probable that the reductions in peripheral oestrogens are contributing to the therapeutic effect and the small reduction accounts for the low response rate compared to anti-oestrogens. It is interesting to note that the patient with the best response of longest duration showed the greatest fall in oestradiol levels. There was no general correlation of hormone suppression with response, and this has been noted for other hormone suppressive therapies (Santen et al., 1982; Harris et al., 1983b) .
This study does not exclude LHRH receptors as a target for Zoladex, but we think that the suppression of oestradiol is a more likely explanation of the low response rate, whereas 20 of 30 patients reported by Eidne et al. (1985) had LHRH receptors in their tumours.
Because of its effect on suppression of ovarian androgens, Zoladex should be further evaluated in combined endocrine therapy, since it may contribute to depletion of androgens that could be an intratumoral substrate for oestrogen production, as well as lowering peripheral oestradiol levels.
